Skip to main content
OpenTrials
Completed

NCT Number: NCT05086471

Performance Evaluation of the NaviCam SB Capsule Endoscope System for the Diagnosis of Small Bowel Diseases

This study uses a comparative method to evaluate the performance of the NaviCam SB capsule endoscope system in comparison to the PillCam SB3 capsule system for the diagnosis of small bowel diseases.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Union Hospital, Tongji Medical College, Huazhong Univerdity of Science and Technology

Wuhan, Hubei, 430022, China

About this study

This study adopts a prospective and self-controlled design. The subjects are adult patients (≥18 years old) who have symptoms of small bowel disease or suspected GI bleeding; Subjects swallow two types of SB capsules approximately 40 minutes apart in a randomized order. During the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time. This study adopts a method of independent image reading in the participating centers. Two physicians of digestive endoscopy respectively review the images captured by the experimental capsule and the control capsule for normal versus abnormal findings, type of findings and categorization (lesions, polyps, bleeding, etc.), capsule transit time, reading time, and image quality.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients (≥18 years old) who have symptoms of small bowel disease or suspected GI bleeding;
  • Those need capsule endoscopy because the recurring GI symptoms cannot be explained by other imaging methods;
  • Those can understand and accept this study protocol and voluntarily sign an informed consent.

Exclusion criteria

  • Patient is expected to undergo MRI examination within 7 days after ingestion of the capsule;
  • Patient with known gastrointestinal motility disorders;
  • Patient with known or suspected gastrointestinal obstruction, stenosis or fistula;
  • Patient with known or suspected delayed gastric emptying;
  • Patient suffers from any condition, such as swallowing problems, which precludes compliance with study and/or device instructions;
  • Patient has any allergy or other known contraindication or intolerance to the medications used in the study;
  • Patient has any condition, which precludes compliance with study and/or device instructions;
  • Women who are either pregnant or nursing at the time of screening;
  • Concurrent participation in another clinical trial using any investigational drug or device;
  • Patient suffers from a life-threatening condition;
  • Patients with history or clinical evidence of renal disease and/or previous clinically significant laboratory abnormalities of renal function parameters;
  • Patients with pace-maker or implantable cardioverter other implantable electronic medical device;
  • Patient with an easily magnetized metal part;
  • Patient requires endoscopic placement of the capsule;
  • Others considered by the investigator not suitable for this study.

Treatment and study plan

NaviCam SB

Device

Subjects swallow two types of SB capsules approximately 40 minutes apart in a randomized order. During the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time.

PillCam SB3

Device

Subjects swallow two types of SB capsules approximately 40 minutes apart in a randomized order. During the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time.

Primary outcomes

  1. Diagnostic agreement rate

    Time frame: 14 days

    The diagnosis of subjects by the two types of small bowel capsule endoscopes through independent image reading, that is, the agreement between the two systems with respect to the diagnosis of normal or abnormal subject.

Secondary outcomes

  1. Intestinal transit time

    Time frame: 14 days

    The time from capsule swallowing to capsule excretion

  2. Ease of swallowing the capsule

    Time frame: 14 days

    The subject's supervisor determines how easy it is to swallow the capsule and which of the following feelings is very easy, easy, moderate, difficult, or very difficult.

  3. diagnosis rate

    Time frame: 14 days

    Comparison of the diagnosis rate (examination results within one week before or after enrollment) with other standard mucosal imaging tools (upper GI endoscopy, enteroscopy, colonoscopy, etc.)

  4. Quality of small bowel images

    Time frame: 14 days

    Comparison of the quality of small intestine pictures taken with the two capsules

  5. Image reading time

    Time frame: 14 days

    Comparison of the reading times of the two capsules

Sponsors and collaborators

Lead sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Other

Collaborators

  • Changhai Hospital
  • Qilu Hospital of Shandong University

Registry information

Official study title

Performance Evaluation of the NaviCam SB Capsule Endoscope System in Comparison to the PillCam SB3 Capsule System for the Diagnosis of Small Bowel Diseases

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Oct 21, 2021
Registry last updated
Sep 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.